Business
AXIM Biotech Advances Programs Through Traditional Biotech Pathways, Positive Meeting with FDA -- SECFilings.com
AXIM Biotech Advances Programs Through Traditional Biotech Pathways, Positive Meeting with FDA -- SECFilings.com.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n REDONDO BEACH, CA, Dec. 13, 2017 (GLOBE NEWSWIRE) -- \n SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc.’s (OTCQB: AXIM) promising clinical trial for the treatment of irritable bowel syndrome (IBS), as well as the company's recent green light from the FDA to submit an IND application for its treatment of patients with chemotherapy-induced nausea and vomiting and AIDS patients experiencing appetite and weight loss. Treating IBS with CBD Imagine waking up in the morning, experiencing stomach cramps, and feeling like you have to be near a bathroom at all times. When leaving the house to work, you must take routes that you know will have public restrooms along the way. This is a reality for up to 20% of American adults that suffer from irritable bowel syndrome at some point in their lives, although doctors don’t know what causes it and there are no cures for the condition. Cannabidiol (CBD) is a non-psychoactive cannabinoid found in cannabis or hemp plants that may be effective in treating a wide range of medical conditions, including arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, depression, antibiotic resistant infection, epilepsy, and other neurological disorders. According to Google Scholar, more than 2,300 studies have been published mentioning CBD in 2017 alone. CBD has been shown to reduce inflammation by acting on the human body’s endocannabinoid system that regulates inflammatory responses, among other things. CB1 receptors are located primarily on central and peripheral neurons, while CB2 receptors are concerned with immune function, inflammation and pain. By influencing these receptors in various ways, cannabinoids have the potential to treat many conditions. In terms of IBS, early research suggests that CBD targets enteric reactive gliosis, counteracts the inflammatory environment induced by lipopolysaccharides in human colonic cultures derived from ulcerative colitis patients, and reduces intestinal damage mediated by the PPAR-gamma receptor pathway. Researchers believe that the modulation of the gut endogenous cannabinoid system could provide a useful therapeutic target for disorders of gastroin...